Xilio Therapeutics Inc (XLO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$8.50-2.41%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · XLO
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | 64.1 | 43.8 | 6.3 | — | — | — | — |
| Operating Expenses & Income | |||||||
| R&D Expenses | 66.8 | 56.0 | 41.2 | 52.1 | 59.2 | 51.2 | 43.9 |
| Operating Income | (31.4) | (42.0) | (60.6) | (79.1) | (89.1) | (75.0) | (54.6) |
| Earnings from Continuing Operations | |||||||
| Other Non-Operating Income / Expenses | 9.5 | 6.9 | 2.3 | 2.7 | 0.9 | (0.8) | — |
| EBT, Incl. Unusual Items | — | (35.0) | — | — | — | — | — |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | |||||||
| Net Income | (21.8) | (35.0) | (58.2) | (76.4) | (88.2) | (75.8) | (55.2) |
| Per Share | |||||||
| Basic EPS | (1.12) | (4.19) | (1.09) | (2.78) | (3.22) | (13.52) | (105.42) |
| Diluted EPS | — | (4.19) | (1.09) | (2.78) | (3.22) | (13.52) | (105.42) |
| Basic Weighted Avg Shares | 19.4 | 8.4 | 53.5 | 27.5 | 27.4 | 5.6 | 0.5 |
| Supplemental | |||||||
| EBITDA | — | (40.4) | (58.9) | (77.2) | (87.3) | (73.5) | (53.5) |
| EBIT | (31.4) | (42.0) | (60.6) | (79.1) | (89.1) | (75.0) | (54.6) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.